122 related articles for article (PubMed ID: 22850367)
21. Echocardiographic Features of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction.
Shah AM; Cikes M; Prasad N; Li G; Getchevski S; Claggett B; Rizkala A; Lukashevich I; O'Meara E; Ryan JJ; Shah SJ; Mullens W; Zile MR; Lam CSP; McMurray JJV; Solomon SD;
J Am Coll Cardiol; 2019 Dec; 74(23):2858-2873. PubMed ID: 31806129
[TBL] [Abstract][Full Text] [Related]
22. The effect of renin-angiotensin system inhibitors on mortality and heart failure hospitalization in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis.
Shah RV; Desai AS; Givertz MM
J Card Fail; 2010 Mar; 16(3):260-7. PubMed ID: 20206902
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of baseline plasma amino-terminal pro-brain natriuretic peptide and its interactions with irbesartan treatment effects in patients with heart failure and preserved ejection fraction: findings from the I-PRESERVE trial.
Anand IS; Rector TS; Cleland JG; Kuskowski M; McKelvie RS; Persson H; McMurray JJ; Zile MR; Komajda M; Massie BM; Carson PE
Circ Heart Fail; 2011 Sep; 4(5):569-77. PubMed ID: 21715583
[TBL] [Abstract][Full Text] [Related]
24. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial.
McKelvie RS; Komajda M; McMurray J; Zile M; Ptaszynska A; Donovan M; Carson P; Massie BM;
J Card Fail; 2010 Feb; 16(2):128-34. PubMed ID: 20142024
[TBL] [Abstract][Full Text] [Related]
25. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.
Paulus WJ; Tschöpe C
J Am Coll Cardiol; 2013 Jul; 62(4):263-71. PubMed ID: 23684677
[TBL] [Abstract][Full Text] [Related]
26. Irbesartan in patients with heart failure and preserved ejection fraction.
Massie BM; Carson PE; McMurray JJ; Komajda M; McKelvie R; Zile MR; Anderson S; Donovan M; Iverson E; Staiger C; Ptaszynska A;
N Engl J Med; 2008 Dec; 359(23):2456-67. PubMed ID: 19001508
[TBL] [Abstract][Full Text] [Related]
27. Worsening renal function and outcome in heart failure patients with preserved ejection fraction and the impact of angiotensin receptor blocker treatment.
Damman K; Perez AC; Anand IS; Komajda M; McKelvie RS; Zile MR; Massie B; Carson PE; McMurray JJ
J Am Coll Cardiol; 2014 Sep; 64(11):1106-13. PubMed ID: 25212644
[TBL] [Abstract][Full Text] [Related]
28. Heart failure with preserved ejection fraction: time for a new approach?
Desai AS
J Am Coll Cardiol; 2013 Jul; 62(4):272-4. PubMed ID: 23684678
[No Abstract] [Full Text] [Related]
29. Clinical Characteristics and Outcomes of Patients With Coronary Artery Disease and Angina: Analysis of the Irbesartan in Patients With Heart Failure and Preserved Systolic Function Trial.
Badar AA; Perez-Moreno AC; Hawkins NM; Jhund PS; Brunton AP; Anand IS; McKelvie RS; Komajda M; Zile MR; Carson PE; Gardner RS; Petrie MC; McMurray JJ
Circ Heart Fail; 2015 Jul; 8(4):717-24. PubMed ID: 26067854
[TBL] [Abstract][Full Text] [Related]
30. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in Heart Failure With Preserved Ejection Fraction Study (I-Preserve) trial.
Zile MR; Gaasch WH; Anand IS; Haass M; Little WC; Miller AB; Lopez-Sendon J; Teerlink JR; White M; McMurray JJ; Komajda M; McKelvie R; Ptaszynska A; Hetzel SJ; Massie BM; Carson PE;
Circulation; 2010 Mar; 121(12):1393-405. PubMed ID: 20231531
[TBL] [Abstract][Full Text] [Related]
31. The partnership between renalase and ejection fraction as a risk factor for increased cardiac remodeling biomarkers in chronic heart failure patients.
Stojanovic D; Mitic V; Stojanovic M; Petrovic D; Ignjatovic A; Stefanovic N; Cvetkovic T; Kocic G; Bojanic V; Deljanin Ilic M
Curr Med Res Opin; 2020 Jun; 36(6):909-919. PubMed ID: 32297799
[No Abstract] [Full Text] [Related]
32. Sacubitril/valsartan reduces ventricular arrhythmias in parallel with left ventricular reverse remodeling in heart failure with reduced ejection fraction.
Martens P; Nuyens D; Rivero-Ayerza M; Van Herendael H; Vercammen J; Ceyssens W; Luwel E; Dupont M; Mullens W
Clin Res Cardiol; 2019 Oct; 108(10):1074-1082. PubMed ID: 30788621
[TBL] [Abstract][Full Text] [Related]
33. Heart failure with preserved ejection fraction: clinical characteristics of 4133 patients enrolled in the I-PRESERVE trial.
McMurray JJ; Carson PE; Komajda M; McKelvie R; Zile MR; Ptaszynska A; Staiger C; Donovan JM; Massie BM
Eur J Heart Fail; 2008 Feb; 10(2):149-56. PubMed ID: 18279770
[TBL] [Abstract][Full Text] [Related]
34. Relation of peripheral collagen markers to death and hospitalization in patients with heart failure and preserved ejection fraction: results of the I-PRESERVE collagen substudy.
Krum H; Elsik M; Schneider HG; Ptaszynska A; Black M; Carson PE; Komajda M; Massie BM; McKelvie RS; McMurray JJ; Zile MR; Anand IS
Circ Heart Fail; 2011 Sep; 4(5):561-8. PubMed ID: 21750125
[TBL] [Abstract][Full Text] [Related]
35. [Heart failure with preserved ejection fraction (HFpEF)].
Maeder MT; Buser M; Brenner R; Rickli H
Ther Umsch; 2018 Sep; 75(3):161-169. PubMed ID: 30145974
[TBL] [Abstract][Full Text] [Related]
36. Understanding heart failure with preserved ejection fraction: clinical importance and future outlook.
Miller AB; Piña IL
Congest Heart Fail; 2009; 15(4):186-92. PubMed ID: 19627293
[TBL] [Abstract][Full Text] [Related]
37. HFNEF, HFpEF, HF-PEF, or DHF: what is in an acronym?
Sanderson JE
JACC Heart Fail; 2014 Feb; 2(1):93-4. PubMed ID: 24622122
[TBL] [Abstract][Full Text] [Related]
38. The irbesartan in heart failure with preserved systolic function (I-PRESERVE) trial: rationale and design.
Carson P; Massie BM; McKelvie R; McMurray J; Komajda M; Zile M; Ptaszynska A; Frangin G;
J Card Fail; 2005 Oct; 11(8):576-85. PubMed ID: 16230259
[TBL] [Abstract][Full Text] [Related]
39. [The I-PRESERVE study].
Trimarco B; Rosei EA
G Ital Cardiol (Rome); 2009 Aug; 10(8):495-8. PubMed ID: 19771745
[No Abstract] [Full Text] [Related]
40. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response.
Kao DP; Lewsey JD; Anand IS; Massie BM; Zile MR; Carson PE; McKelvie RS; Komajda M; McMurray JJ; Lindenfeld J
Eur J Heart Fail; 2015 Sep; 17(9):925-35. PubMed ID: 26250359
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]